| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99d66bfce7f10af935959208c035817e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94e3404a41d7f378ed33d2f47b6be517 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8121 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5306
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54306 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58 |
| filingDate |
2020-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81ba43356c42c03bf8308682ee2a487d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95c05698ae7c6fbc70644e963ed338a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cf186862620a310d7f09f395ddb709b |
| publicationDate |
2021-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3148161-A1 |
| titleOfInvention |
Anti-drug antibody assay |
| abstract |
Provided is an immunoassay for detection of anti-drug antibodies (ADAs), such as anti-C1-lnhibitor antibodies (C1 INH-ADA) in a test sample. The immunoassay provides a means for testing the immunogenicity and efficacy of drug treatment protocols. The immunoassay comprises the steps of (i) acidic dissociation of the anti-drug antibodies from the drug within a provided test sample; (ii) neutralization of the test sample containing the dissociated drug-ADA complexes; (iii) incubation of the sample with excess binding affinity-labeled drug; (iv) capture of the resulting ADA-binding affinity labeled drug complexes on an affinity binding substrate surface; (v) addition of tagged anti-human antibodies; and (vi) quantification of captured affinity-labeled drug-ADA complexes. |
| priorityDate |
2019-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |